Michael Carella
Endocrinology, Diabetes & Metabolism · Lansing, MINPI 1790737542
Payments from drug & device makers
Across 267 payments — averaging $13.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$401
- Lilly USA, LLC$325
- Welch Allyn$192
- Merck$167
- Boehringer Ingelheim$110
- plus $1K from 35 others
What the payments were for
- Food & beverage$3,28294%
- Other$1926%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NONE$192
How this compares
$3,473 in reported general payments places this provider in the 55th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 74 | $96,138 |
| OzempicSemaglutide | 47 | $79,682 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $35,671 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $24,826 |
| TrulicityDulaglutide | 13 | $22,113 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $13,585 |
| Levothyroxine Sodium | 318 | $4,416 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $4,231 |
| Novolog FlexpenInsulin Aspart | 15 | $3,619 |
| SynthroidLevothyroxine Sodium | 13 | $1,683 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,315 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 11 | $1,086 |
| Rosuvastatin Calcium | 35 | $843 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 11 | $713 |
| Metformin Hcl ErMetformin Hcl | 34 | $653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $110 | $96,13874 claims |
| Novo NordiskOzempic | $1,140 | $79,68247 claims |
| Lilly USA, LLCTrulicity | $325 | $22,11313 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $4,416318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Lansing
- Kara HoisingtonLansing$178K
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.